| | |
| | |
| Clinical data | |
|---|---|
| Trade names | Brovana |
| Other names | Arformoterol tartrate (USAN US) |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a602023 |
| License data |
|
| Routes of administration | Inhalation |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 52–65% |
| Elimination half-life | 26 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H24N2O4 |
| Molar mass | 344.411 g·mol−1 |
| |
| | |
Arformoterol, sold under the brand name Brovana among others, is a medication used for the treatment of chronic obstructive pulmonary disease (COPD). [1] [2]
It is a long-acting β2 adrenoreceptor agonist (LABA) and it is the active (R,R)-(−)-enantiomer of formoterol. [1] It was approved for medical use in the United States in October 2006. [1] It is available as a generic medication. [3]
Arformoterol is indicated for the maintenance treatment of bronchoconstriction in people with chronic obstructive pulmonary disease (COPD). [1]